New York, New York--(Newsfile Corp. - November 12, 2026) - Investors who suffered losses on The Chemours Company ("The Chemours" or the "Company") (NYSE: CC) stock may have claims to recover those losses. Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors that a federal securities class action has been filed on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired The Chemours securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). Investors who wish to serve as lead plaintiff must move the Court no later than December 7, 2026.

Investors with losses on The Chemours securities can contact Faruqi & Faruqi partner Josh Wilson about the The Chemours class action to learn about their legal rights and options.

Key facts for The Chemours investors

• Class Period: between February 20, 2026 and August 4, 2026
• Lead plaintiff deadline: December 7, 2026
• Disclosure: August 4, 2026
• Stock drop: $3.34 per share, or 18.63%

What happened?
On August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results, including a reduction of its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously), and management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

"The Chemours stock fell 18.63% on August 5, 2026 after the August 4, 2026 disclosure described in the complaint. The complaint alleges that investors bought The Chemours shares during the Class Period without the full picture."

What does the complaint allege?
The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Next steps for The Chemours investors
Faruqi & Faruqi, LLP is reviewing potential claims on behalf of The Chemours investors. Investors with losses can visit www.faruqilaw.com/CC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss the The Chemours class action.

If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Common questions from The Chemours investors
Who is eligible? Investors who purchased or otherwise acquired The Chemours securities between February 20, 2026 and August 4, 2026 and lost money may have claims, and can contact the firm to learn whether the The Chemours class action affects them.

What is a securities class action? A lawsuit brought on behalf of a group of investors who bought shares at prices alleged to have been inflated by false or misleading statements, in violation of the federal securities laws. The The Chemours class action alleges that the Company and its executives made such statements.

Has a lawsuit been filed? Yes. A federal securities class action has been filed against The Chemours. Investors who wish to serve as lead plaintiff must move the Court by December 7, 2026. Investors who do nothing remain absent class members, and serving as lead plaintiff is not required to share in any recovery.

Does it cost anything to contact the firm? No. Investors who purchased The Chemours securities during the Class Period may contact Faruqi & Faruqi, LLP to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Whistleblower notice
Faruqi & Faruqi, LLP also encourages anyone with information regarding The Chemours's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Individuals with original information may also consider the SEC Whistleblower Program, which can award whistleblowers 10 to 30 percent of the monetary sanctions collected in a successful SEC enforcement action when those sanctions exceed $1 million.

About Faruqi & Faruqi, LLP
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Related links

• The Chemours class action, Faruqi & Faruqi, LLP
• The Chemours Company SEC filings index, EDGAR
• SEC Whistleblower Program
• Faruqi & Faruqi, LLP

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323587

Source: Faruqi & Faruqi LLP